NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02446405,Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer,https://clinicaltrials.gov/study/NCT02446405,ENZAMET,ACTIVE_NOT_RECRUITING,"The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.",NO,Prostatic Neoplasms,DRUG: Enzalutamide|DRUG: NSAA|DRUG: LHRHA or Surgical Castration,"Overall Survival Time, the interval from the date of randomisation to date of death., 3 years","Prostate specific antigen progression free survival time, the interval from the date of randomisation to the date of first evidence of PSA progression, clinical progression, or death from any cause, whichever occurs first, or the date of last known follow-up without PSA progression

PSA progression is defined as: a rise in PSA by more than 25% AND more than 2ng/mL, 3 years|Clinical progression free survival time, the interval from the date of randomisation to the date of first clinical evidence of disease progression or death from any cause, whichever occurs first, or the date of last known follow-up without clinical progression, 3 years|Adverse events, The NCI Common Terminology Criteria for Adverse Events version 4 (CTCAE v4.03) will be used to classify and grade the intensity of adverse events during study treatment, 3 years|Health-related quality of life (EORTC Core Quality of Life Questionnaire (QLQ C-30), Quality of Life Questionnaire for Prostate Cancer (PR-25), Euroqol 5 item preference-based measure of health (EQ-5 D-5L)), HRQL will be reported by participants using the EORTC core quality of life questionnaire (QLQ C-30) and prostate cancer specific module (PR-25). The EQ-5D-5L will be used to derive utility scores suitable for quality adjusted survival analyses, 3 years|Healthcare resource cost-effectiveness (incremental cost effectiveness ratio), Information on the following areas of health-care resource usage will be collected: hospitalisations, visits to health professionals, and medications Australian unit costs will be applied to the resource usage data to estimate the incremental cost of the addition of enzalutamide to standard treatment, 3 years",,University of Sydney,Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cancer Trials Ireland|Canadian Cancer Trials Group|Astellas Pharma Inc,MALE,"ADULT, OLDER_ADULT",PHASE3,1125,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ANZUP 1304|ACTRN12614000110684,2014-03,2026-12-31,2027-06-30,2015-05-18,,2025-03-25,"Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, 2450, Australia|Concord Cancer Centre - Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Nepean Cancer Care Centre, Kingswood, New South Wales, 2747, Australia|St. George Hospital, Kogarah, New South Wales, 2217, Australia|Central West Cancer Services, Orange, New South Wales, 2800, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, 2444, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Genesis Care North Shore, St Leonards, New South Wales, 2065, Australia|Tamworth Rural Referral Hospital, Tamworth, New South Wales, 2340, Australia|The Tweed Hospital, Tweed Heads, New South Wales, 2485, Australia|Riverina Cancer Care Centre, Wagga Wagga, New South Wales, 2650, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, 2076, Australia|Wollongong Hospital, Wollongong, New South Wales, 2500, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, 0810, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|Townsville Hospital, Douglas, Queensland, 4814, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4006, Australia|Gold Coast University Hospital, Southport, Queensland, 4215, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Adelaide Cancer Centre - Ashford Cancer Care Centre, Kurralta Park, South Australia, 5037, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|Monash Cancer Centre Moorabbin, Bentleigh East, Victoria, 3165, Australia|Peter MacCallum Cancer Centre - East Melbourne, East Melbourne, Victoria, 3002, Australia|St. Vincents Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|Peninsula South Eastern Haematology & Oncology Group- Peninsula Oncology Centre, Frankston, Victoria, 3199, Australia|University Hospital Geelong, Geelong, Victoria, 3220, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Australian Urology Associates, Malvern, Victoria, 3144, Australia|Eastern Health Box Hill Hospital, Melbourne, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Border Medical Oncology, Wodonga, Victoria, 3690, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Fiona Stanley Hospital (formerly Royal Perth Hospital), Perth, Western Australia, 6000, Australia|Prostate Cancer Institute - Southern Alberta Institute of Urology, Calgary, Alberta, T2V 1P9, Canada|Cross Cancer Institute, Edmonton, Alberta, AB T6G 1Z2, Canada|BCCA - Fraser Valley Cancer Center, Surrey, British Columbia, BC V3V 1Z2, Canada|BCCA Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Horizon Health Network - Dr Everett Chalmers Hospital, Fredericton, New Brunswick, NB E3B 5N5, Canada|Saint John Regional Hospital, Saint John, New Brunswick, NB E2L 4L4, Canada|QEII Health Sciences Centre, Capital District Health Authority, Halifax, Nova Scotia, NS B3H 2Y9, Canada|Cambridge Memorial Hospital, Cambridge, Ontario, ON N1R 7S6, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, ON K7L 5P9, Canada|London Regional Cancer Program, London, Ontario, N6A 5W9, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, ON L1G 2B9, Canada|Ottawa Hospital Cancer Centre, Ottawa, Ontario, ON K1H 8L6, Canada|Algoma District Cancer Program Sault Area Hospital, Sault Ste. Marie, Ontario, P6B 0A8, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, ON P7B 6V4, Canada|University Health Network - Princess Margaret Hospital, Toronto, Ontario, ON M5G 2M9, Canada|Hôpital Notre-Dame, Montreal, Quebec, H2L 4M1, Canada|CHUQ-Pavillon Hotel-Dieu de Quebec, Québec City, Quebec, QC G1R 2J6, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada|Beaumont Hospital, Beaumont, Dublin, Dublin 9, Ireland|Beacon Private Hospital, Dublin, Dublin 18, Ireland|St Vincent's University Hospital, Dublin, Dublin 4, Ireland|Mater Misercordiae University Hospital, Dublin, Dublin 7, Ireland|Mater Private Hospital, Dublin, Dublin 7, Ireland|St James Hospital, Dublin, Dublin 8, Ireland|Galway University Hospital, Galway, Ireland|Adelaide and Meath Hospital - National Children's Hospital, Tallaght, Dublin 24, Ireland|University Hospital Waterford, Waterford, Ireland|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, 8140, New Zealand|Waikato Hospital, Hamilton, 3204, New Zealand|Royal Cornwall Hospital, Truro, Cornwall, TR1 3LQ, United Kingdom|Royal Sussex Hospital, Brighton, East Sussex, BN2 5BE, United Kingdom|Kent and Canterbury Hospital, Canterbury, Kent, CT1 3NG, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, AB25 2ZN, United Kingdom|Velindre Cancer Centre, Cardiff, Wales, CF14 2TL, United Kingdom|University College Hospital London, London, NW1 2BU, United Kingdom|Guys and St Thomas Hospital, London, SE1 9RT, United Kingdom|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom|University Hospital Southampton, Southampton, SO16 6YD, United Kingdom|Great Western Hospital, Swindon, SN3 6BB, United Kingdom",
